NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/25/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization874.52 mln
Float42.42 mln
Earnings Date11/11/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
3418
Highly suspicious
1-Year Forecast
29.10
Transformational upside
Relative Strength
98
/ 100
Top performer
Debt / Equity
0.10
Very low leverage
ROE
-41.57
Deeply negative
Business Description
4D Molecular Therapeutics is a late-stage biotech company based in Emeryville, California, with operations in the Netherlands, that develops gene therapy treatments using its proprietary vector discovery platform. Its most advanced therapy, 4D-150, targets retinal diseases such as wet age-related macular degeneration and diabetic macular edema by delivering long-lasting treatment through a single eye injection. The company has additional programs in earlier stages of development targeting cystic fibrosis, geographic atrophy, and a rare lung disease, and works in partnership with Otsuka Pharmaceutical.